• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

随着时间的推移,结直肠癌的治疗效果有所改善,但仅限于左侧疾病患者。

Improvement in colorectal cancer outcomes over time is limited to patients with left-sided disease.

机构信息

Gastrointestinal Cancer Center, Ordensklinikum Linz, Seilerstaette 4, 4010, Linz, Austria.

Medical Faculty, Johannes Kepler University, Linz, Austria.

出版信息

J Cancer Res Clin Oncol. 2022 Nov;148(11):3007-3014. doi: 10.1007/s00432-021-03868-0. Epub 2022 Jan 3.

DOI:10.1007/s00432-021-03868-0
PMID:34977964
Abstract

PURPOSE

Incidence and mortality of colorectal cancer (CRC) declined over the last decades. However, survival depends on the primary tumor location. It is unknown if all progress in outcomes vary depending on left-sided (LCRC) versus right-sided (RCC) colorectal cancer. We compare incidence and mortality rates over time according to the primary tumor location.

METHODS

Data from the Austrian National Cancer Registry spanning from 1983 to 2018 were used to calculate annual incidence and mortality rates and survival stratified by primary tumor localization and stage. Joinpoint regression with linear regression models were used on different subgroups to identify significant changes of incidence- and mortality slopes.

RESULTS

A total of 168,260 (incidence dataset) and 87,355 cases (mortality dataset) were identified. Survival of disseminated RCC was worse compared to LCRC (HR 1.14; CI 1.106-1.169). Total and LCRC incidence and mortality rates declined steadily over time, whereas the rates of RCC did not. Incidence of disseminated RCC declined significantly less (slope - 0.07; CI - 0.086; - 0.055) than in LCRC (slope - 0.159; CI - 0.183; - 0.136); mortality rate of RCC was unchanged over time. Incidence and mortality of localized RCC remained unchanged over time, whereas both rates declined independently of stage in LCRC.

CONCLUSION

Colorectal cancer outcomes during the last 35 years have preferentially improved in LCRC but not in RCC, indicating that the progress made is limited to LCRC. It is necessary to define RCC as a distinct form of CRC and to focus on specific strategies for its early detection and treatment.

摘要

目的

在过去几十年中,结直肠癌(CRC)的发病率和死亡率有所下降。然而,生存取决于原发肿瘤的位置。目前尚不清楚所有在结局方面取得的进展是否因左半结直肠癌(LCRC)与右半结直肠癌(RCC)而有所不同。我们根据原发肿瘤位置比较了随时间推移的发病率和死亡率。

方法

使用 1983 年至 2018 年期间的奥地利国家癌症登记处的数据,计算按原发肿瘤定位和分期分层的年度发病率和死亡率以及生存率。使用线性回归模型对不同亚组进行 Joinpoint 回归,以确定发病率和死亡率斜率的显著变化。

结果

共确定了 168260 例(发病率数据集)和 87355 例(死亡率数据集)病例。转移性 RCC 的总生存情况比 LCRC 差(HR 1.14;95%CI 1.106-1.169)。总的和 LCRC 的发病率和死亡率随时间稳步下降,而 RCC 的发病率则没有。转移性 RCC 的发病率显著下降(斜率-0.07;95%CI-0.086;-0.055),低于 LCRC(斜率-0.159;95%CI-0.183;-0.136);RCC 的死亡率随时间不变。局部 RCC 的发病率和死亡率随时间保持不变,而在 LCRC 中,这两个比率均独立于分期而下降。

结论

在过去的 35 年中,LCRC 的结直肠癌结局得到了改善,但 RCC 没有,这表明所取得的进展仅限于 LCRC。有必要将 RCC 定义为一种独特的 CRC 形式,并专注于针对其早期检测和治疗的特定策略。

相似文献

1
Improvement in colorectal cancer outcomes over time is limited to patients with left-sided disease.随着时间的推移,结直肠癌的治疗效果有所改善,但仅限于左侧疾病患者。
J Cancer Res Clin Oncol. 2022 Nov;148(11):3007-3014. doi: 10.1007/s00432-021-03868-0. Epub 2022 Jan 3.
2
Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases.经动脉(化疗)栓塞与全身化疗治疗结直肠癌肝转移。
Cochrane Database Syst Rev. 2024 Aug 9;8(8):CD012757. doi: 10.1002/14651858.CD012757.pub2.
3
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
6
Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.阿司匹林用于心血管疾病和癌症一级预防的预防性使用:系统评价和综述概述。
Health Technol Assess. 2013 Sep;17(43):1-253. doi: 10.3310/hta17430.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.大剂量化疗及自体造血干细胞救援用于高危神经母细胞瘤患儿
Cochrane Database Syst Rev. 2015 Oct 5;2015(10):CD006301. doi: 10.1002/14651858.CD006301.pub4.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
10
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.大剂量化疗及自体造血干细胞救援用于高危神经母细胞瘤患儿
Cochrane Database Syst Rev. 2013 Aug 22(8):CD006301. doi: 10.1002/14651858.CD006301.pub3.

引用本文的文献

1
Current concepts of anti-EGFR targeting in metastatic colorectal cancer.转移性结直肠癌中抗表皮生长因子受体靶向治疗的当前概念
Front Oncol. 2022 Nov 17;12:1048166. doi: 10.3389/fonc.2022.1048166. eCollection 2022.
2
Development and validation of a survival prediction model for 113,239 patients with colon cancer: a retrospective cohort study.113239例结肠癌患者生存预测模型的开发与验证:一项回顾性队列研究
J Gastrointest Oncol. 2022 Oct;13(5):2393-2405. doi: 10.21037/jgo-22-878.

本文引用的文献

1
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone.转移性结直肠癌:叶酸-氟嘧啶化疗骨干的进展。
Cancer Treat Rev. 2021 Jul;98:102218. doi: 10.1016/j.ctrv.2021.102218. Epub 2021 May 4.
2
European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer.欧洲 2021 年癌症死亡率预测,重点关注胰腺癌和女性肺癌。
Ann Oncol. 2021 Apr;32(4):478-487. doi: 10.1016/j.annonc.2021.01.006. Epub 2021 Feb 21.
3
Improvement of Survival over Time for Colorectal Cancer Patients: A Population-Based Study.
结直肠癌患者随时间推移生存率的改善:一项基于人群的研究。
J Clin Med. 2020 Dec 14;9(12):4038. doi: 10.3390/jcm9124038.
4
Complete mesocolic excision for colon cancer: is it worth it?结肠癌的完整结肠系膜切除术:值得吗?
J Gastrointest Oncol. 2019 Dec;10(6):1215-1221. doi: 10.21037/jgo.2019.05.01.
5
An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients.结直肠癌患者 25 年发病、治疗和转归概述。
Int J Cancer. 2018 Dec 1;143(11):2758-2766. doi: 10.1002/ijc.31785. Epub 2018 Sep 29.
6
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.奥地利芦可替尼治疗骨髓纤维化:治疗管理共识
Wien Klin Wochenschr. 2018 Sep;130(17-18):495-504. doi: 10.1007/s00508-018-1365-5. Epub 2018 Jul 24.
7
European cancer mortality predictions for the year 2018 with focus on colorectal cancer.2018 年欧洲癌症死亡率预测,重点关注结直肠癌。
Ann Oncol. 2018 Apr 1;29(4):1016-1022. doi: 10.1093/annonc/mdy033.
8
The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review.原发肿瘤位置对转移性结直肠癌患者的预测价值:一项系统评价。
Crit Rev Oncol Hematol. 2018 Jan;121:1-10. doi: 10.1016/j.critrevonc.2017.11.003. Epub 2017 Nov 7.
9
Colorectal cancer screening: An updated review of the available options.结直肠癌筛查:现有可选方案的最新综述。
World J Gastroenterol. 2017 Jul 28;23(28):5086-5096. doi: 10.3748/wjg.v23.i28.5086.
10
Pattern and Dynamics of Distant Metastases in Metastatic Colorectal Cancer.转移性结直肠癌远处转移的模式与动态变化
Visc Med. 2017 Mar;33(1):70-75. doi: 10.1159/000454687. Epub 2017 Feb 7.